Jasper Therapeutics doses first patient in chronic inducible urticaria study


Jasper Therapeutics has initiated a phase 1b/2a clinical trial, called SPOTLIGHT, to evaluate subcutaneous briquilimab for the treatment of chronic inducible urticaria. Briquilimab is a novel antibody therapy that targets c-Kit in mast cell-driven diseases. The first patient has been dosed in the study, which aims to establish proof of concept for mast cell depletion by briquilimab in chronic inducible urticaria. The trial plans to enroll a total of 15 patients and is expected to release preliminary data in the second half of 2024. Primary endpoints include safety and tolerability, while secondary endpoints encompass efficacy and pharmacokinetics.

Source link

error: Content is protected !!